WASHINGTON, April 24 -- US President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic treatments and increase federal funding for research into their use in response to advocates for the drug ‌ibogaine including influential podcaster Joe Rogan.

Presently almost all psychedelic drugs in the United States are considered Schedule I controlled substances, in the same class as heroin or ecstasy, meaning they are deemed to have no medical use and high risk for abuse.

Several treatments derived from psychedelic compounds are being tested by drugmakers. Here is what is known about these treatments:

What are the ‌drugs being tested for?

The strongest evidence for use of th...